%0 Journal Article
%T Atrial fibrillation in cryptogenic stroke and transient ischaemic attack ¨C The Nordic Atrial Fibrillation and Stroke (NOR
%A Andrej Netland Khanevski
%A Anna Tancin Lambert
%A Anne Gulsvik
%A Anne Hege Aamodt
%A Barbara Ratajczak-Tretel
%A Bente Halvorsen
%A Christina Kruuse
%A Christine Jonassen
%A Christine Kremer
%A Dan Atar
%A David Russell
%A Else Charlotte Sandset
%A Erik Eriksen
%A Grete K Bakkejord
%A Guri Hagberg
%A Guttorm Eld£¿en
%A Halvor N£¿ss
%A Hege Ihle-Hansen
%A Henriette Johansen
%A H£¿kon Ihle-Hansen
%A H£¿kon Tobro
%A Ingvild Nakstad
%A Jesper S£¿mark
%A Karen L £¿gidius
%A Kathrine Arntzen
%A Linn Hofs£¿y Steffensen
%A Maja Villseth
%A Martin Kurz
%A Mehdi Rezai
%A Raheel Shafiq
%A Siv B Krogseth
%A Stein-Helge Tingvoll
%A Susanne Ingebrigtsen
%A Thomas C Truelsen
%A Titto Idicula
%A Vigdis Bjerkeli
%A Vojtech Novotny
%J European Stroke Journal
%@ 2396-9881
%D 2019
%R 10.1177/2396987319837089
%X Paroxysmal atrial fibrillation is often suspected as a probable cause of cryptogenic stroke. Continuous long-term ECG monitoring using insertable cardiac monitors is a clinically effective technique to screen for atrial fibrillation and superior to conventional follow-up in cryptogenic stroke. However, more studies are needed to identify factors which can help selecting patients with the highest possibility of detecting atrial fibrillation with prolonged rhythm monitoring. The clinical relevance of short-term atrial fibrillation, the need for medical intervention and the evaluation as to whether intervention results in improved clinical outcomes should be assessed. The Nordic Atrial Fibrillation and Stroke Study is an international, multicentre, prospective, observational trial evaluating the occurrence of occult atrial fibrillation in cryptogenic stroke and transient ischaemic attack. Patients with cryptogenic stroke or transient ischaemic attack from the Nordic countries are included and will have the Reveal LINQ£¿ Insertable cardiac monitor system implanted for 12 months for atrial fibrillation detection. Biomarkers which can be used as predictors for atrial fibrillation and may identify patients, who could derive the most clinical benefit from the detection of atrial fibrillation by prolonged monitoring, are being studied. The primary endpoint is atrial fibrillation burden within 12 months of continuous rhythm monitoring. Secondary endpoints are atrial fibrillation burden within six months, levels of biomarkers predicting atrial fibrillation, CHA2DS2-VASc score, incidence of recurrent stroke or transient ischaemic attack, use of anticoagulation and antiarrhythmic drugs, and quality of life measurements. The clinical follow-up period is 12 months. The study started in 2017 and the completion is expected at the end of 2020
%K Cryptogenic stroke
%K atrial fibrillation
%K insertable cardiac monitor
%K biomarkers
%K arrhythmia monitoring
%K anticoagulation
%K Nordic Atrial Fibrillation and Stroke Study
%U https://journals.sagepub.com/doi/full/10.1177/2396987319837089